prikaz prve stranice dokumenta Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease
  Download
PDF 783.26 KB
Scientific paper - Original scientific paper
Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease
Journal of Personalized Medicine, 13 (2023); 870. https://doi.org/10.3390/jpm13050870
Cini Tešar, Eleonora; Mikolašević, Ivana; Skočiliš, Iva; Redžović, Arnela; Vučinić, Damir; Marušić, Jasna; Đorđević, Gordana

Citations:
,
Cite this document

Cini Tešar, E., Mikolašević, I., Skočiliš, I., Redžović, A., Vučinić, D., Marušić, J. & Đorđević, G. (2023). Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease. Journal of Personalized Medicine, 13.. doi: 10.3390/jpm13050870

Cini Tešar, Eleonora, et al. "Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease." Journal of Personalized Medicine, vol. 13, 2023. https://doi.org/10.3390/jpm13050870

Cini Tešar, Eleonora, Ivana Mikolašević, Iva Skočiliš, Arnela Redžović, Damir Vučinić, Jasna Marušić and Gordana Đorđević. "Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease." Journal of Personalized Medicine 13 (2023). https://doi.org/10.3390/jpm13050870

Cini Tešar, E., et al. (2023) 'Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease', Journal of Personalized Medicine, 13. doi: 10.3390/jpm13050870

Cini Tešar E, Mikolašević I, Skočiliš I, Redžović A, Vučinić D, Marušić J, and sur.. Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease. Journal of Personalized Medicine [Internet]. 2023 May 22 [cited 2025 April 11];13. doi: 10.3390/jpm13050870

E. Cini Tešar, et al., "Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease", Journal of Personalized Medicine, vol. 13, May 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:447771. [Accessed: 11 April 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Prostate Cancer Scoring Index for Risk of Progression of Radioresistant Disease
AuthorEleonora Cini Tešar
AuthorIvana Mikolašević
AuthorIva Skočiliš
AuthorArnela Redžović
AuthorDamir Vučinić https://orcid.org/0000-0002-5804-0799
AuthorJasna Marušić
AuthorGordana Đorđević
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Oncology and Radiotherapy)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of General Pathology and Pathological Anatomy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract (english)
Prostate cancer (Pca) is among the most common malignant diseases in men and the fourth leading cause of death worldwide. Surgery and radical radiotherapy (RT) remain the gold standard for the treatment of localized or locally advanced prostate cancer. The efficiency of radiotherapy treatment is limited by toxic side effects due to dose escalation. Cancer cells often develop radio-resistant mechanisms that are related to the DNA repair, inhibition of apoptosis or changes in cell cycle. Based on... More our earlier research on biomarkers that are involved in those cellular mechanisms (p53, bcl-2, NF-kb, Cripto-1 and Ki67 proliferation) and correlation with clinico-pathological parameters (age, PSA value, Gleason score, grade group, prognostic group), we created the numerical index for risk of tumor progression in patients with radioresistant tumors. For each of these parameters, the strength of association with disease progression was statistically assessed, and a specific number of points was assigned proportional to the strength of the correlation. Statistical analysis identified an optimal cut-off score of 22 or more as an indicator of significant risk for progression with a sensitivity of 91.7% and a specificity of 66.7%. The scoring system in the retrospective receiver operating characteristic analysis showed AUC of 0.82. The potential value of this scoring is the possibility of identifying patients with clinically significant radioresistant Pca. Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleJournal of Personalized Medicine
Numberingvol. 13, 870
p-ISSN2075-4426
DOIhttps://doi.org/10.3390/jpm13050870
URN:NBNurn:nbn:hr:184:447771
Publication2023-05-22
Document URLhttps://doi.org/10.3390/jpm13050870
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-05-22 11:43:04
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.